Vedolizumab for inflammatory bowel diseasesI
Aim of review. To present literature data on administration of vedolizumab at inflammatory bowel diseases. Summary. The vedolizumab is anti-α4β7-integrin humanized class IgG1 antibodies which suppresses migration of leukocytes in intestinal tissue, interfering thereby with development of pathol...
Saved in:
| Main Authors: | Igor L. Khalif, M. V. Shapina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/99 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study)
by: L. . Khalif, et al.
Published: (2018-08-01) -
Noninvasive markers of inflammatory bowel disease activity
by: A. V. Nikitin, et al.
Published: (2018-08-01) -
Extraintestinal manifestations of inflammatory bowel diseases: arthropathy and arthritis
by: Gulustan Hamid Sadygova
Published: (2018-08-01) -
Colonic growth factors (G-CSF, GM-CSF) and chemokines (MCP-1, MIP-1β) in severe ulcerative colitis
by: Yevgeny A. Konovich, et al.
Published: (2018-08-01) -
БОЛЕЗНЬ ВЕГЕНЕРА: ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ
by: Н. В. Сицко, et al.
Published: (2025-03-01)